Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Pharmaceuticals

Real-time Estimate Cboe BZX 12:40:09 2024-03-28 pm EDT 5-day change 1st Jan Change
2.09 USD -3.69% Intraday chart for Fortress Biotech, Inc. +5.58% -30.90%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target MT
Certain Preferred Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024. CI
Certain Common Stock of Fortress Biotech, Inc. are subject to a Lock-Up Agreement Ending on 8-FEB-2024. CI
Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc CI
Fortress Biotech Prices $11 Million Offering of Stock, Warrants; Shares Sink in Early Trading MT
Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating MT
Top Midday Gainers MT
Fortress Biotech Insider Bought Shares Worth $2,664,776, According to a Recent SEC Filing MT
Fortress Biotech Insider Bought Shares Worth $249,999, According to a Recent SEC Filing MT
Earnings Flash (FBIO) FORTRESS BIOTECH Posts Q3 Revenue $34.8M MT
Fortress Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Wall Street Set to Open Slightly Higher as Investors Parse Powell Remarks MT
Top Premarket Decliners MT
Fortress Biotech Begins Public Offering of Units MT
Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg) CI
Fortress Biotech Announces 1-for-15 Reverse Stock Split MT
Avenue Therapeutics, Inc. announced that it expects to receive $0.55 million in funding from Fortress Biotech, Inc. and other investor CI
B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating MT
Fortress Biotech CEO Rosenwald Buys 20,000 Shares for $210,900 MT
Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Earnings Flash (FBIO) FORTRESS BIOTECH Reports Q2 Revenue $17.4M MT
Fortress Biotech Unit Urica Says Study of Dotinurad Shows Comparable Profile Between Healthy US, Japanese Subjects MT
Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell Microcap Value Index CI
Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 3000E Value Index CI
Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell Microcap Growth Index CI
Chart Fortress Biotech, Inc.
More charts
Fortress Biotech, Inc. is a biopharmaceutical company that acquires, develops and commercializes pharmaceutical and biotechnology products and product candidates. The Company markets its various branded dermatology products, Qbrexza, Accutane, Amzeeq, Zilxi, Ximino, Exelderm and Targadox. Qbrexza (glycopyrronium 2.4%) is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis in adults and children nine years and older. Accutane (isotretinoin) is an oral capsule for the treatment of severe recalcitrant nodular acne. Amzeeq (minocycline 4%) topical foam is a topical minocycline treatment for the inflammatory lesions of non-nodular moderate to severe acne vulgaris in adults and children nine years and older. Zilxi (minocycline 1.5%) is a topical foam and a topical minocycline treatment for inflammatory lesions of rosacea in adults. Ximino (minocycline hydrochloride) is an oral minocycline drug for the treatment of moderate to severe acne.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.17 USD
Average target price
6.333 USD
Spread / Average Target
+191.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Fortress Biotech, Inc. - Nasdaq
  4. News Fortress Biotech, Inc.
  5. Fortress Biotech : Cyprium Therapeutics Report Positive Clinical Data for Menkes Disease